We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Celgene Corporation | NASDAQ:CELG | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 108.24 | 109.30 | 109.37 | 0 | 01:00:00 |
From May 2019 to May 2024
By Donato Paolo Mancini
Roche Holding AG's (ROG.EB) Tecentriq has been granted U.S. Food & Drug Administration priority review status in combination with Abraxane for the treatment of a type of breast cancer, the company said Tuesday.
FDA priority reviews are granted to treatments that are determined to have the potential to provide significant improvements in treatment, prevention, or diagnosis of a disease.
The review for the initial, or first-line, treatment of unresectable locally advanced or metastatic triple-negative breast cancer would be for those patients whose disease expresses a protein called PD-L1, Roche said.
If approved, the company said this combination would be the first cancer immunotherapy regimen for that type of cancer.
Abraxane is a registered trademark of Abraxis Bioscience, LLC, which is wholly owned by Celgene Corp. (CELG).
The FDA is expected to make a decision on approval by March 12, 2019, Roche said.
Write to Donato Paolo Mancini at donatopaolo.mancini@dowjones.com; @donatopmancini
(END) Dow Jones Newswires
November 13, 2018 01:28 ET (06:28 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Celgene Chart |
1 Month Celgene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
